Advantage of HSP110 (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients by Berardinelli, Gustavo Noriz et al.
Oncotarget28691www.oncotarget.com
Advantage of HSP110 (T17) marker inclusion for microsatellite 
instability (MSI) detection in colorectal cancer patients
Gustavo Noriz Berardinelli1, Cristovam Scapulatempo-Neto1, Ronílson Durães1,2, 
Marco Antônio de Oliveira3, Denise Guimarães1,4 and Rui Manuel Reis1,5,6
1Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
2Department of Oncology, Barretos Cancer Hospital, Jales, São Paulo, Brazil
3Nucleus of Epidemiology and Biostatistics, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
4Department of Endoscopy, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
5Life and Health sciences Research Institute, University of Minho, Gualtar Campus, Braga, Portugal
6ICVS/3B’s-PT Government Associate Laboratory, Gualtar Campus, Braga, Portugal
Correspondence to: Rui Manuel Reis, email: ruireis.hcb@gmail.com
Keywords: colorectal cancer; microsatellite instability; molecular diagnostic; immunohistochemistry; HSP110 (T17)
Received: November 02, 2017    Accepted: April 04, 2018    Published: June 19, 2018
Copyright: Berardinelli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
Colorectal cancer (CRC) is a leading cause of cancer death worldwide. 
Microsatellite instability (MSI) is a genetic pathway leading to CRC, associated 
with particular clinicopathological features, and recently a major biomarker of 
immunotherapy response. There is little information the frequency MSI among 
Brazilian CRC patients, and it is still debatable the ideal methodology for MSI screening 
in countries with limited resources. We proposed to evaluate MSI by molecular and 
immunohistochemistry (IHC) methods, to compare both methodologies and also to 
assess the inclusion of a novel microsatellite marker, HSP110 (T17). The molecular 
MSI evaluation was performed using a PCR-multiplex panel in a total of 1013 CRC 
patients. Mismatch repair (MMR) proteins (MLH1, MSH2, MSH6 and PMS2) expression 
were evaluated by IHC. HSP110 (T17) marker was analyzed by fragment analysis. 
Molecularly, 89.5% of cases were MSI-negative and 10.5% were MSI-positive. The 
IHC showed that 88.9% of cases exhibited MMR-proficient status, 10.2% were MMR-
deficient and 0.9% was inconclusive. Genotyping of the HSP110 (T17) in 106 MSI-
positive and 215 MSI-negative cases showed its alteration only among the MSI-
positive cases. We observed agreement (0.956, Kappa Test) between both molecular 
and IHC methodologies, with only eight discordant results, and in this subset of cases 
the HSP110 (T17) corroborate the molecular findings. This study suggests the use of 
molecular assays over IHC for MSI analysis and proposes the inclusion HSP110 (T17) 
marker as a complementary analysis in discordant cases.
INTRODUCTION
Colorectal cancer (CRC) is a common diagnosis 
in high-income countries and its incidence is rising in 
middle-income countries, including Brazil [1–3]. In US, 
it is the second largest cause of cancer-related deaths 
when both sexes are combined [2]. Five-year survival rate 
is about 50%, with no differences between high-income 
countries (49% average) and low- and middle-income 
countries (44% average) [1]. In Brazil, CRC is the third 
most common cause of cancer for men and the second for 
women with approximately 30,000 new cases diagnosed 
per year for both genders [3]. The incidence rates are 
increasing due to population aging, increasing smoking 
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rates, changes in diet style and the absence of wide spread 
screening programs [4].
Initiation and progression of CRC involve 
different molecular mechanisms responsible for distinct 
clinicopathological features and behavior of tumors [5]. 
A large body of evidence suggests that tumor location 
(left versus right) drives carcinogenesis [5, 6], and 
genomics abnormalities occur in a non-random pattern in 
the evolution of adenoma-carcinoma then metastasis [7]. 
Chromosomal instability (CIN), microsatellite instability 
(MSI) and CpG island methylation phenotype (CIMP) 
are genetical pathways involved in the development of 
CRCs affecting oncogenes, tumor suppressor genes and 
DNA repair mechanisms [7, 8]. More recently, CRC have 
been subtyped molecularly in four consensus molecular 
subtypes (CMSs) based on gene expression with 
distinguishing features: CMS1 (microsatellite instability 
immune, 14%), hypermutated, microsatellite unstable 
and strong immune activation; CMS2 (canonical, 37%), 
epithelial, marked WNT and MYC signaling activation; 
CMS3 (metabolic, 13%), epithelial and evident metabolic 
dysregulation; and CMS4 (mesenchymal, 23%), 
prominent transforming growth factor–beta activation, 
stromal invasion and angiogenesis [9].
MSI occurs when Mismatch Repair (MMR) 
proteins (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, 
and PMS2) are absent due to mutations or promoter 
hypermethylation in hereditary and sporadic forms, 
respectively [10, 11]. These DNA repair proteins are 
important to repair base-base mismatches occurring during 
DNA replication; thus their loss leads to an accumulation 
of DNA replication errors, particularly in areas of the 
genome with short repetitive nucleotide sequences, known 
as microsatellites [12]. Genes containing microsatellite 
regions are known as MSI-target genes and are involved 
in several functions related with carcinogenesis, such as 
DNA repair, DNA damage sensor, apoptosis, signalization, 
proliferation etc [11, 13]. As the alterations occur in a 
random matter, the findings suggest a different progression 
of each MSI-positive tumor, a model in which the MSI 
mutator phenotype develops in gradual steps by successive 
alterations of the different MSI-target genes [11, 14–16].
Hereditary Nonpolyposis Colorectal Cancer 
(HNPCC) or Lynch Syndrome is the most frequent 
hereditary colorectal cancer syndromes and is the result 
of the presence of germline mutations in MMR genes, 
mainly MLH1 and MSH2 with somatic inactivation of the 
remaining wild-type allele [10, 17]. On the other hand, in 
sporadic CRC, MSI phenotype is less frequent (12-15%) 
and is predominantly due to loss of MLH1 function, 
caused by transcriptional silencing of the gene brought 
about by abnormal methylation of MLH1 promoter 
region [18].
Clinically, MSI positive CRCs are associated 
with several features, such as proximal location, poorly 
differentiated histology, intense lymphocytic infiltration, 
favorable prognosis compared to MSI negative CRCs, 
and lower risk of metastasis [6, 19]. There are also several 
evidences suggesting that MSI positive patients are less 
responsive to 5-Fluorouracil-based chemotherapy (5-FU), 
and more responsive to irinotecan based regimens [19–
22]. Recently, MSI phenotype was reported as a predictive 
biomarker of response to immunotherapy treatments, 
more specifically anti-PD-1 therapy [23, 24]. Therefore, 
MSI is a useful molecular marker not only for diagnostic 
and prognostic purposes, but also for therapy prediction 
response in CRC patients, being currently, a crucial 
biomarker for CRC management [24, 25].
Nowadays, immunohistochemistry (IHC) and 
molecular methods are the most common assays for MSI 
assessment in CRCs. IHC, will detect the loss expression 
of MMR proteins in tumor tissue compared to adjacent 
normal, thus resulting in presence or absence of MMR 
proteins expression (MMR-proficiency versus -deficiency) 
[22].
Molecularly, MSI status can be assessed by PCR 
analysis of informative microsatellite markers, either 
mononucleotide and dinucleotide repeats, which are 
further analyzed by capillary sequencing [26, 27]. An 
initial panel of genetic markers, known as Bethesda panel, 
was established at a National Cancer Institute’s (NCI) 
workshop, and includes two mononucleotide (BAT25 and 
BAT26) and three dinucleotide (D5S346, D2S123, and 
D17S250) repeats; this assay requires including matched-
normal DNA as a reference [26]. Later, a subsequent 
NCI’s workshop re-evaluated the Bethesda panel and 
recommended the substitution of dinucleotide repeats 
by quasi-monomorphic mononucleotide repeat markers 
(BAT25, BAT26, NR21, NR24, and NR27), which allow 
performing the assay only in tumor DNA, thus avoiding 
the use of paired normal DNA [28]. This method classified 
tumors as high microsatellite instability (MSI-H) when at 
least two of five markers are instable, low microsatellite 
instability (MSI-L) when only one marker is instable and 
microsatellite stability (MSS) [27, 29].
Recently, we implemented an optimized molecular 
assay for MSI evaluation for the Brazilian population 
[27]. We established a quasi-monomorphic variation range 
(QMVR) for each marker in a Brazilian healthy population 
allowing the use of MSI markers without matching normal 
DNA, which was independent of the ethnicity, even in the 
highly admixed population of Brazil [27].
Recently it has been reported a high frequency 
of mutation of the HSP110 microsatellite T17 
(mononucleotide repeat retained in intron 8) in MSI-
positive CRC cases [14]. Changes in this region have 
been shown to be important because of their association 
with biological effects leading to an increased synthesis 
of a variant HSP110 isoform due to exon 9 skipping 
(HSP110DE9) [14, 15]. Chaperone proteins including 
HSP110 are expressed in specific set of stress conditions 
promoting the survival of malignant cells in colon 
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cancers [30]. Deletions in HSP110 (T17) were shown to 
increase the sensitivity of CRC cells to 5-Fluorouracil 
and oxaliplatin [15]. Therefore, analysis of HSP110 
(T17) was become an important tool for the identification 
of MSI-positive CRC cases and the appropriate clinical 
management of patients.
There is little information on MSI in Brazilian CRC 
patients and there is still some controversies concerning 
the ideal approach for MSI screening. So, in the present 
study we proposed to evaluate MSI by molecular and 
IHC methods in a large set of Brazilian CRC patients, to 
compare both methodologies, and to improve the analysis 
of discordant cases.
RESULTS
Determination of MSI phenotype by MMR 
immunohistochemistry
Expression analysis of MMR proteins (MLH1, 
MSH6, MSH2 and PMS2) was performed in 996/1013 
CRC cases by immunohistochemistry (IHC). In a total 
of 17 cases there was not enough biological material 
for the analysis. Among those cases, 88.9% (886/996) 
presented expression of the four MMR proteins, thus 
being considered positive, 10.2% (102/996) exhibited loss 
of expression of at least one of the four MMR proteins 
and thus considered negative, and 0.9% (8/996) were 
considered inconclusive since the internal positive controls 
were negative (Figure 1A). Among the negative IHC cases, 
52.0% (53/102) presented loss of MLH1/PMS2 and 20.6% 
(21/102) loss of MSH2/MHS6. We also observed: 1.9%, 
2.9%, 7.9% and 6.9% of cases presenting isolated loss 
of MLH1, MSH2, MSH6 and PMS2, respectively. Other 
combinations of loss protein expression were observed in 
7.8% (8/102) of cases and none of cases showed loss of 
expression of the all four proteins.
Determination of MSI phenotype by molecular 
analysis
All 1,013 CRC were analyzed for MSI by molecular 
analysis. We observed that 85.8% (870/1013) of cases 
were MSS, 3.7% (37/1013) were MSI-L and 10.5% 
(106/1013) were MSI-H (Figure 1B and Figure 2). We 
further grouped together the MSS and MSI-L cases, 
named: MSI-negative (MSS+MSI-L), while the MSI-H 
cases were named: MSI-positive [11, 16, 31].
Validation, sensitivity, specificity and accuracy of 
molecular MSI analysis
Using IHC as gold standard to determine the 
microsatellite instability, the agreement analysis between 
the methodologies was performed by the Kappa Test 
(Table 1). Considering that positive IHC status should 
represent MSI-negative status and that negative IHC status 
corresponding to MSI-positive status, we observed that the 
Measure of Agreement between the techniques was 0.956 
(p <0.001) (Table 1).
Hence, the sensitivity, specificity and accuracy 
of the molecular MSI analysis was: 99.5%, 96.1% and 
99.2%, respectively (Table 2).
Determination of HSP110 (T17) QMVR and 
tumor genotyping
A recent report suggests HSP110 (T17) has value 
as a complementary marker in MSI determination [32]. 
In order to evaluate the role HSP110 (T17) in our cohort, 
we initially determined its quasi-monomorphic variation 
range (QMVR). For that, a total of 214 DNA from healthy 
subjects were analyzed to determine the normal range. All 
the 214 samples were successfully amplified, generating 
428 alleles. The allele size was monomorphic with only 
two observed alleles: 131 and 132 base pairs. The 131 bp 
allele was observed in 234/428 (54.7%) alleles (Figure 3A) 
and the 132 base pair was seen in 194/428 (45.3%) alleles. 
Therefore, we determined the HSP110 (T17) QMVR as 
130-133 bp, since ±1 bp variations can occur from different 
reagents and equipment’s used in the analyses [28, 33].
Following the QMVR determination, we further 
genotyped the HSP110 (T17) in the tumor tissue from 
CRC patients, namely in MSI-positive cases (MSI-H=106) 
and MSI-negative cases (subsets of MSS=180 and of 
MSI-L=35). In MSI-negative cases, all of them exhibited 
the HSP110 (T17) within QMVR above determined. In 
MSI-positive cases, 7.6% (8/106) were inconclusive, due 
to very poor DNA quality. Among the conclusive cases 
we observed 5.1% (5/98) of cases without alterations, 
and 94.9% (93/98) with altered HSP110 (T17), exhibiting 
alleles with losses of up to 6 bp in relation to the QMVR 
(Figure 3B) and aberrant peak ratios.
Discordant IHC and molecular MSI results
Despite the high agreement between IHC and 
molecular methodologies, we observed discordant results in 
eight cases (Table 3, Supplementary Table 1). In these cases, 
we assessed the HSP110 (T17) marker, which showed to 
be alterated in the four MSI-H/positive-IHC cases (Table 3, 
Supplementary Table 1). The two MSS/negative-IHC and 
two MSI-L/negative-IHC cases also showed presence of 
HSP110 (T17) alteration (Table 3,  Supplementary Table 1).
DISCUSSION
In colorectal cancer (CRC), the presence of MSI 
has been used as a biomarker for several purposes: i) 
hereditary screening; ii) prognostic marker, where stage 
II/III tumors presenting MSI have a better prognosis 
than those that do not present it; iii) 5-FU resistance 
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Figure 1:﻿ (A) Percentage of MMR IHC status for 996 Brazilian CRC patients; Positive IHC status: 88.9% (886/996), Negative IHC status: 
10.2% (102/996) and Inconclusive IHC status 0.9% (8/996). (B) Percentage of molecular MSI status for 1013 Brazilian CRC patients; 
MSS (microsatellite stability): 85.8% (870/1013), MSI-L (low-microsatellite instability): 3.7% (37/1013) and MSI-H (high-microsatellite 
instability): 10.5% (106/1013).
Figure 2:﻿ (A) Fragment analysis of peaks for molecular MSI analysis in one MSS CRC sample with five markers (NR27, NR21, NR24, 
BAT25 and BAT26) within of the quasi-monomorphic variation range (QMVR). (B) Fragment analysis of peaks for molecular MSI analysis 
in one MSI-H CRC sample with five markers (NR27, NR21, NR24, BAT25 and BAT26) outside of the QMVR. Arrow indicates the allele 
outside of the QMVR. bp – base pair.
Table 1:﻿ Measure of Agreement (Kappa Test) between immunohistochemistry (IHC) and molecular MSI analyses
IHC status (n) Molecular MSI status (n) Measure of Agreement
MSI- (886) MSI- (882)
0.956 (p<0,001)
MSI+ (4)
MSI+ (102) MSI-(4)
MSI+ (98)
+: positive, -: negative, n: number of cases
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and irinotecan sensitivity [34]; and more recently iv) 
immunotherapy response [23, 24].
Therefore, the identification of MSI plays 
a major role in cancer management and different 
analytical methodologies are currently used, being 
immunohistochemistry (IHC) and molecular testing 
(microsatellite markers) the most widespread. Both 
techniques are suggested in the American Society of 
Clinical Oncology (ASCO) and National Comprehensive 
Cancer Network (NCCN) guidelines for evaluation of MSI 
[35, 36]. The methodology of choice can be associated 
a several factor, such as expertise of the laboratory, 
availability of technology and overall costs. In the present 
study we intended to compare different methodologies in 
a Brazilian routine setting. We analyzed 1,013 CRC cases 
and used a pentaplex PCR assay previously validated by 
our group in the Brazilian population [27]. We observed 
85.8% of MSS cases, 3.7% of MSI-L cases and 10.5% 
of MSI-H cases. By IHC analysis, we observed that 
10.2% of the cases exhibited MSI, with a Measure of 
Agreement (Kappa test) of 0.956 between both IHC and 
molecular methods. Besides the high level of agreement, 
the sensitivity, specificity and accuracy of the molecular 
test were 99.5%, 96.1% and 99.2%, respectively, when 
the IHC was used as the gold standard. Our results are 
in accordance with previous series. Patil et al [37] used 
a panel of five markers similar to those used in our study 
and the agreement between the techniques was 100%. 
Cicek et al [38] used a panel that included mononucleotide 
and dinucleotide markers and the cases identified by 
MSI and IHC were highly concordant when using the 
cutoff of 30% or greater for instable molecular markers. 
Zhang [39] compared both methods and concluded that 
molecular MSI is as sensitive and specific as IHC, given 
its excellent reproducibility and its potential capability 
to indicate mutations not be detected by IHC. Molecular 
MSI has been used and will continue to prevail as the 
primary screening tool for identifying HNPCC patients. To 
some extent, molecular MSI and IHC are complementary 
to each other in identifying HNPCC [39]. Lindor et al 
[40] evaluated both methods and the predictive value of 
abnormal IHC was 100% for an MSI-H phenotype and 
that testing strategies must take into account acceptability 
of missing some cases of MSI-H tumors if only IHC 
is performed. At variance, Lin et al [41] obtained 23 
(32.9%) discordant cases for the same comparison 
between methodologies. The panel of molecular markers 
used by Lin et al [41] may justify this high percentage 
of discordance, where, dinucleotide markers are known 
to be less sensitive compared to mononucleotide markers 
Table 2:﻿ Estimation of sensitivity, specificity and accuracy of molecular MSI analysis
IHC-negative (n) IHC-positive (n) Total
MSI-positive (MSI-H) 98 4 102
MSI-negative (MSS+MSI-L) 4 882 886
Total 102 886 988
MSS: microsatellite stability, MSI-L: low-microsatellite instability, MSI-H: high-microsatellite instability, n: number of cases.
Table 3:﻿ Summary of cases with discordant data between immunohistochemistry and molecular MSI analysis
Sample ID IHC status MLH1 MSH2 MSH6 PMS2 Molecular MSI 
status
HSP110 (T17) 
status
11.0011 negative + + + - MSS altereda
12.0767 negative - + + - MSS altereda
11.0226 negative + + - + MSI-L altereda
13.0395 negative + + + - MSI-L altereda
11.0404 positive + + + + MSI-H altered
11.0827 positive + + + + MSI-H altered
13.0578 positive + + + + MSI-H altered
13.1023 positive + + + + MSI-H altered
HSP110 (T17) status obtained by comparison between normal and tumor tissue DNA from the samples and also by R method.
+: positive protein expression; -: negative protein expression; MSS: microsatellite stability; MSI-L: low-microsatellite 
instability; MSI-H: high-microsatellite instability; a: analyzed by R method.
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[42], which were used in our study. In addition, it was 
been reported that the molecular analysis is less prone to 
change than IHC due to neoadjuvant and radiation therapy 
in CRC, therefore, the ideal methodology, to assess MSI 
status after neoadjuvant therapy [43].
Despite the high agreement among methodologies, 
we observed disagreement in eight cases. Recently, 
HSP110 (T17) marker has been proposed as a 
complementary marker in MSI assessment [32]. Therefore, 
we initially determined the QMVR of HSP110 (T17) in 
a Brazilian healthy population. This analysis showed the 
monomorphic nature of the marker. We further assess 
this marker in MSI-positive cases and observed 94.9% 
with altered HSP110 (T17). This value was as high as the 
values obtained by Dorard et al [14], Collura et al [15], 
Buhard et al [32] and Markovic et al [44] of HSP110 
(T17) changes in MSI-positive cases, which reported a 
frequency of 100%, 97%, 98.7% and 100%, respectively. 
Altogether, these results suggest that HSP110 is the most 
mutated MSI-target gene in MSI-positive CRC [14]. 
Importantly, in the discordant cases, all four MSI-H/IHC-
positive cases presented alteration in HSP110 (T17), and 
in the two MSS/IHC-negative cases and in the two MSI-L/
negative-IHC cases the HSP110 (T17) was also alterated, 
suggesting a higher sensitivity of HSP110 (T17) to detec 
MSI compared to pentaplex, in agreement with recent 
findings of Buhard et al [32].
The HSP110, like other heat shock proteins 
(HSP), protects cells against adverse conditions, acts 
as a nucleotide exchange factor for HSP70 and acts as 
a major chaperone [45, 46]. Because of this activity, 
HSP110 is a good antigen-carrying protein and is used as 
an extracellular protein in the vaccine formulation [47]. 
Although, its tumorigenic properly is not fully understood, 
in CRC is suggested to preventing cells to entry in 
apoptosis [48].
Both techniques compared herein are routinely 
used and each one has advantages and disadvantages. 
IHC has the advantages of being applicable in formalin-
fixed, paraffin-embedded tissues (FFPE), easy to perform, 
affordable, and able to guide the mutation screening of 
MMR genes. On the other hand, IHC can only assess a 
limited number of proteins, it is vulnerable to the quality 
of tissue preparation, and heavily depends on pathologist 
interpretation [39, 49]. The molecular technique has 
several advantages: i) it is applicable in formalin-fixed 
paraffin-embedded tissues (FFPE); ii) it does not need 
an expert pathologist for analysis; iii) it is objective and 
highly accurate compared to the subject evaluation of 
the staining pattern of the IHC slides; iv) it can identify 
Figure 3:﻿ (A) The allele 131 of HSP110 (T17) marker was the most observed in 54.7% (234/428) of analyzed alleles from healthy 
individuals blood DNA. (B) Two alleles (131 and 126) of HSP110 (T17) marker were observed in MSI-H CRC tumor DNA showing 
alteration in this marker. Arrow indicates the allele outside of the QMVR. bp – base pair.
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MSI-positive tumors that present defects in MMR but 
have protein staining due to a non-truncated missense 
mutation or to mutations in other MMR proteins which 
are not included in the IHC panel; v) it is feasible in small 
biopsies [50]; vi) is less disposed to change than IHC 
following neoadjuvant and radiation therapy, and vii) it 
has a low cost per patient when the assay is performed 
in-house. However, it has the disadvantage of the need 
of a molecular genetic facility and specialized staff, and 
like the IHC, the FFPE pre-analytic issues, such as tissue 
fixation, can also interfere with PCR reaction [22, 37, 39]. 
In the present study we used an optimize in-house assay 
that does not need matched adjacent normal tissue [27], 
thus leading to a more cost-efficient assay when compared 
with four immunohistochemistry (MLH1, MSH2, MSH6 
and PMS2) reactions. Despite of the similar results, our 
findings suggest that the molecular MSI assay, with the 
use of pentaplex plus HSP110 (T17) marker leads to a 
more accurate MSI determination and it is less sensitive 
to pre-analytic issues in compared with IHC. Therefore, it 
is the ideal methodology for the routine assessment of MSI 
for CRC management in a low resource country as Brazil.
We observed an MSI-positive frequency of 10%, 
which is in line with international reports that vary 
between 12-16% of CRC patients [8, 51, 52]. The slightly 
lower frequency described can be due to several factors, 
such as: tumor staging; different criteria for inclusion of 
patients, different ethnicities of the patients’ analyzed, and 
environmental criteria that may affect the presence of MSI 
in the CRC.
In conclusion, the present study elucidated the MSI 
frequency in a robust manner by analyzing a large series of 
Brazilian CRC patients, who exhibited a known admixture 
ancestry [27]. Our results suggests that molecular analysis 
correlates better with the MSI phenotype in the CRC, and 
the HSP110 (T17) improves the MSI determination in a 
routine setting of a Brazilian Cancer Hospital.
MATERIALS AND METHODS
Participants
In the present study 1013 CRC patients diagnosed 
between 2010 and 2014 at Barretos Cancer Hospital, 
Barretos, São Paulo, Brazil were enrolled. CRC patients 
were referred by the Departments of Digestive Surgery 
and Oncogenetic for MSI testing. Surgery-based cases 
presented CRC with no information of the hereditary 
context, whereas the Oncogenetic-based cases had 
confirmed or high clinical suspicion of familial CRC 
syndromes. Patients came mainly from the Southeast 
region of Brazil (77,7%), followed by Midwest (8,6%) 
and Northeast (8,1%), and few from the other Brazilian 
regions. Of the total of 1013 cases, 96.3% (976/1013) 
were Surgery-based cases and 3.7% (37/1013) were 
Oncogenetic-based cases, being 1.8% (18/1013) confirmed 
Lynch syndrome cases, 1.5% (15/1013) confirmed 
Familial Adenomatous Polyposis (FAP) syndrome cases 
and 0.4% (4/1013) of unclassified hereditary syndrome. 
Among patients, 52.1% were male and the mean age was 
57.8 years (standard deviation 13.9 years). Concerning 
tumor location, 25.2% were right sided, 51.3% located at 
left colon/proximal rectum and 23.5% at middle rectum/
distal rectum.
We also evaluated 214 healthy individuals from the 
BioBank at Barretos Cancer Hospital, Barretos, São Paulo, 
Brazil. The average age of the individuals was 33 years 
old, 52.3% were male, and 90% of the individuals came 
from the Southeast region of Brazil (São Paulo and Minas 
Gerais states), whereas others came from Paraná, Rio 
Grande do Sul, Bahia, Mato Grosso, Mato Grosso do Sul, 
Paraíba, Pernambuco, and Rondônia regions. This study 
was approved by the IRB at our institution (600/2012).
DNA isolation
Tumor FFPE DNA were isolated using QIAamp 
DNA Micro Kit (Qiagen, Hilden, Germany) following 
the manufacturer’s instructions. DNA was isolated from 
5-μm formalin fixed paraffin-embedded (FFPE) tissue 
slides. Briefly, tissues were deparaffinized by a serial 
extraction with xylene and ethanol (100%, 70%, 50%), 
and separately pathologist selected tumor areas were 
macrodissected using a sterile needle and carefully 
collected into a 1,5 mL PCR tube.
Blood DNA from healthy individuals was isolated 
using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, 
Germany) following the manufacturer’s instructions.
Mismatch repair immunohistochemistry
FFPE tissue blocks were cut into 3 μm sections for 
immunohistochemistry (IHC) using Dako EnVision™ 
FLEX detection system Kit (Dako, Glostrup, Denmark) and 
Autostainer Link 48 equipment (Dako, Glostrup, Denmark) 
following the manufacturer’s instructions. Antigen retrieval 
process was done at 97°C by 20 minutes (pH 9.0). 
Endogenous peroxidases were blocked with EnVision™ 
FLEX Peroxidase-Blocking Reagent (Dako, Glostrup, 
Denmark). The primary antibodies anti-human used in this 
study were: FLEX monoclonal mouse anti-MutL protein 
homolog 1 (MLH1) (clone ES05, ref IS079, ready-to-use, 
Dako, Glostrup, Denmark); FLEX monoclonal mouse 
anti-MutS protein homolog 2 (MSH2) (clone FE11, ref 
IR085, ready-to-use, Dako, Glostrup, Denmark); FLEX 
monoclonal rabbit anti-postmeiotic segregation increased 
2 (PMS2) (clone EP51, ref IR087, ready-to-use, Dako, 
Glostrup, Denmark); and FLEX monoclonal rabbit anti-
MutS protein homolog 6 (MSH6) (clone EP49, ref IR086, 
ready-to-use, Dako, Glostrup, Denmark). The DAB 
solution was used for immunostaining visualization. Slides 
were counterstained with hematoxylin. Nuclear staining 
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of normal epithelial cells, lymphocytes, and stromal cells 
served as positive internal controls in each case. All cases 
were analyzed by one expert pathologist (CSN) who, based 
on nuclear staining, classified each protein by its expression. 
Regardless of the intensity or the extent of cell staining, the 
positive status was found for the cases that showed staining 
(presence of the expression of the protein under analysis) 
and the negative status when no staining was present 
(absence of expression of the protein under analysis).
Molecular microsatellite instability (MSI)
The MSI evaluation was performed using a 
multiplex PCR comprising five quasi-monomorphic 
mononucleotide repeat markers (BAT25, BAT26, NR21, 
NR24, and NR27) as reported [27]. Primer sequences 
were described elsewhere [28]. Each antisense primer 
was end labeled with a fluorescent dye: FAM for BAT26 
and NR21; VIC for BAT25 and NR27; and NED for 
NR24. PCR was performed using the Qiagen Multiplex 
PCR Kit (Qiagen, Hilden, Germany), with 1 μl of DNA 
at 50 ng/μl and the following thermocycling conditions: 
15 min at 95° C; 40 cycles of 95° C for 30 s, 55° C for 
90 s and 72° C for 30 s; and a final extension at 72° C for 
40 min. PCR products were then submitted to capillary 
electrophoresis on an ABI 3500XL Genetic Analyzer 
(Applied Biosystems, Foster City, USA) according to the 
manufacturer’s instructions. The results were analyzed 
using GeneMapper v4.1 (Applied Biosystems, Foster 
City, USA) software to measure the fragment length in 
base pairs.
Cases with 2 or more markers out of quasi-
monomorphic variation range (QMVR) were classified as 
MSI-H (MSI-High), cases with only one marker out of 
QMVR were classified as MSI-L (MSI-Low) and cases 
without markers out of QMVR were classified as MSS 
(Microsatellite stability), as reported [27].
Determination of the HSP110 (T17) QMVR
Blood DNA samples from 214 healthy individuals 
were used to determine the quasi-monomorphic variation 
range (QMVR) of HSP110 (T17). The determined QMVR 
was tested in MSI-negative CRC cases (MSS=180 and 
MSI-L=37) and in MSI-positive CRC cases (MSI-H=90), 
with DNA samples extracted from FFPE cancer tissue.
PCR was performed using 5 μL of Qiagen Multiplex 
PCR Kit (Qiagen, Hilden, Germany), 1 μL of primers [1 mM] 
(Forward primer: 5’TGGGAAGTGTTCATGTGCTC3’ and 
Reverse primer: 5’TGAATCATGGTTCCAGATCAGA3’), 
3 μL of water and 1 μl of DNA at 50 ng/μl and the following 
thermocycling conditions: 15 min at 95° C; 30 cycles of 
94° C for 30 s, 55° C for 90 s and 72° C for 30 s; and a 
final extension at 72° C for 40 min. PCR products were 
then submitted to capillary electrophoresis on an ABI 
3500XL Genetic Analyzer (Applied Biosystems, Foster 
City, USA) according to the manufacturer’s instructions and 
the results were analyzed using GeneMapper v4.1 (Applied 
Biosystems, Foster City, USA) software.
HSP110 (T17) was also analyzed by R method, 
whose determination was calculated using the height ratios 
between peaks, namely R1 (between T14 and T16) and R2 
(between T15 and T16), as described [31].
Author contributions
Conceived and designed the experiments: GNB, 
RMR. Performed the experiments: GNB, CSN. Analyzed 
the data: GNB, CSN, RD, MAO, DPG, RMR. Contributed 
reagents/materials/analysis tools: GNB, CSN, RD, MAO, 
DPG, RMR. Wrote the initial manuscript: GNB, RMR. 
Revised the manuscript: GNB, CSN, RD, MAO, DPG, 
RMR. Supervised the study: RMR.
ACKNOWLEDGMENTS
The authors would like to thank Dr Marta Viana-
Pereira for her technical advices and Dr Eduardo Vilar for 
his critical review of the manuscript.
CONFLICTS OF INTEREST
The authors declare no potential conflicts of interest.
FUNDING
The present study was partially supported by a 
MCT/FINEP/CT-INFRA- PROINFRA 02/2010 grant.
REFERENCES
1. Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl 
K, Chavarri-Guerra Y, St Louis J, Villarreal-Garza C, 
Unger-Saldana K, Ferreyra M, Debiasi M, Liedke PE, 
Touya D, Werutsky G, et al. Planning cancer control in Latin 
America and the Caribbean. Lancet Oncol. 2013; 14:391–
436. https://doi.org/10.1016/S1470-2045(13)70048-2.
2. Siegel RL, Miller KD, Jemal A. Cancer 
Statistics, 2017. CA Cancer J Clin. 2017; 67:7–30. 
https://doi.org/10.3322/caac.21387.
3. INCA. Estimativa 2016: Incidência de Câncer no Brasil. 
Rio de Janeiro: INCA. 2016: 124.
4. Meyerhardt JA, Mayer RJ. Systemic therapy for 
colorectal cancer. N Engl J Med. 2005; 352:476–87. 
https://doi.org/10.1056/NEJMra040958.
5. Yahagi M, Okabayashi K, Hasegawa H, Tsuruta M, 
Kitagawa Y. The worse prognosis of right-sided compared 
with left-sided colon cancers: a systematic review and 
meta-analysis. J Gastrointest Surg. 2016; 20:648–55. 
https://doi.org/10.1007/s11605-015-3026-6.
Oncotarget28699www.oncotarget.com
6. Lee MS, Menter DG, Kopetz S. Right versus left colon 
cancer biology: integrating the consensus molecular 
subtypes. J Natl Compr Canc Netw. 2017; 15:411–9.
7. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: 
molecular basis of colorectal cancer. N Engl J Med. 2009; 
361:2449–60. https://doi.org/10.1056/NEJMra0804588.
8. Boland CR, Goel A. Microsatellite instability in colorectal 
cancer. Gastroenterology. 2010; 138:2073–87.e3. 
https://doi.org/10.1053/j.gastro.2009.12.064.
9. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker 
A, Soneson C, Marisa L, Roepman P, Nyamundanda G, 
Angelino P, Bot BM, Morris JS, Simon IM, et al. The 
consensus molecular subtypes of colorectal cancer. Nat 
Med. 2015; 21:1350–6. https://doi.org/10.1038/nm.3967.
10. Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. 
Milestones of lynch syndrome: 1895-2015. Nat Rev Cancer. 
2015; 15:181–94. https://doi.org/10.1038/nrc3878.
11. Kim TM, Laird PW, Park PJ. The landscape of microsatellite 
instability in colorectal and endometrial cancer genomes. Cell. 
2013; 155:858–68. https://doi.org/10.1016/j.cell.2013.10.015.
12. Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite 
instability in colorectal cancer: prognostic, predictive, and 
therapeutic implications. Clin Cancer Res. 2012; 18:1506–12. 
https://doi.org/10.1158/1078-0432.CCR-11-1469.
13. Shima K, Morikawa T, Yamauchi M, Kuchiba A, Imamura 
Y, Liao X, Meyerhardt JA, Fuchs CS, Ogino S. TGFBR2 and 
BAX mononucleotide tract mutations, microsatellite instability, 
and prognosis in 1072 colorectal cancers. PLoS One. 2011; 
6:e25062. https://doi.org/10.1371/journal.pone.0025062.
14. Dorard C, de Thonel A, Collura A, Marisa L, Svrcek M, 
Lagrange A, Jego G, Wanherdrick K, Joly AL, Buhard O, 
Gobbo J, Penard-Lacronique V, Zouali H, et al. Expression 
of a mutant HSP110 sensitizes colorectal cancer cells to 
chemotherapy and improves disease prognosis. Nat Med. 
2011; 17:1283–9. https://doi.org/10.1038/nm.2457.
15. Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, 
Guilloux A, Wanherdrick K, Dorard C, Taieb A, Saget A, 
Loh M, Soong R, Zeps N, et al. Patients with colorectal 
tumors with microsatellite instability and large deletions 
in HSP110 T17 have improved response to 5-fluorouracil-
based chemotherapy. Gastroenterology. 2014; 146:401–11 
e1. https://doi.org/10.1053/j.gastro.2013.10.054.
16. Hause RJ, Pritchard CC, Shendure J, Salipante SJ. 
Classification and characterization of microsatellite 
instability across 18 cancer types. Nat Med. 2016; 22:1342–
50. https://doi.org/10.1038/nm.4191.
17. Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond 
Lynch syndrome. Clin Gastroenterol Hepatol. 2014; 
12:1059–68. https://doi.org/10.1016/j.cgh.2013.08.015.
18. Li X, Yao X, Wang Y, Hu F, Wang F, Jiang L, Liu Y, Wang 
D, Sun G, Zhao Y. MLH1 promoter methylation frequency 
in colorectal cancer patients and related clinicopathological 
and molecular features. PLoS One. 2013; 8:e59064. 
https://doi.org/10.1371/journal.pone.0059064.
19. Kheirelseid EA, Miller N, Chang KH, Curran C, Hennessey 
E, Sheehan M, Kerin MJ. Mismatch repair protein expression 
in colorectal cancer. J Gastrointest Oncol. 2013; 4:397–408. 
https://doi.org/10.3978/j.issn.2078-6891.2013.021.
20. Hartman DJ, Brand RE, Hu H, Bahary N, Dudley B, Chiosea 
SI, Nikiforova MN, Pai RK. Lynch syndrome-associated 
colorectal carcinoma: frequent involvement of the left colon 
and rectum and late-onset presentation supports a universal 
screening approach. Hum Pathol. 2013; 44:2518–28. 
https://doi.org/10.1016/j.humpath.2013.06.012.
21. Devaud N, Gallinger S. Chemotherapy of MMR-
deficient colorectal cancer. Fam Cancer. 2013; 12:301–6. 
https://doi.org/10.1007/s10689-013-9633-z.
22. Lech G, Slotwinski R, Krasnodebski IW. The role of tumor 
markers and biomarkers in colorectal cancer. Neoplasma. 
2014; 61:1–8.
23. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling 
H, Eyring AD, Skora AD, Luber BS, Azad NS, 
Laheru D, Biedrzycki B, Donehower RC, Zaheer 
A, et al. PD-1 Blockade in Tumors with Mismatch-
Repair Deficiency. N Engl J Med. 2015; 372:2509–20. 
https://doi.org/10.1056/NEJMoa1500596.
24. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, 
Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong 
F, Azad NS, Rucki AA, et al. Mismatch repair deficiency 
predicts response of solid tumors to PD-1 blockade. Science. 
2017; 357:409–13. https://doi.org/10.1126/science.aan6733.
25. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius 
B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana 
J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, et al. 
ESMO Consensus Guidelines for management of patients 
with colon and rectal cancer. a personalized approach to 
clinical decision making. Ann Oncol. 2012; 23:2479–516. 
https://doi.org/10.1093/annonc/mds236.
26. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle 
A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin 
R, Hamilton SR, Hiatt RA, Jass J, et al. Revised Bethesda 
Guidelines for hereditary nonpolyposis colorectal cancer 
(Lynch syndrome) and microsatellite instability. J Natl 
Cancer Inst. 2004; 96:261–8.
27. Campanella NC, Berardinelli GN, Scapulatempo-Neto C, Viana 
D, Palmero EI, Pereira R, Reis RM. Optimization of a pentaplex 
panel for MSI analysis without control DNA in a Brazilian 
population: correlation with ancestry markers. Eur J Hum Genet. 
2014; 22:875–80. https://doi.org/10.1038/ejhg.2013.256.
28. Buhard O, Cattaneo F, Wong YF, Yim SF, Friedman 
E, Flejou JF, Duval A, Hamelin R. Multipopulation 
analysis of polymorphisms in five mononucleotide 
repeats used to determine the microsatellite instability 
status of human tumors. J Clin Oncol. 2006; 24:241–51. 
https://doi.org/10.1200/JCO.2005.02.7227.
29. Buhard O, Suraweera N, Lectard A, Duval A, Hamelin R. 
Quasimonomorphic mononucleotide repeats for high-level 
microsatellite instability analysis. Dis Markers. 2004; 20:251–7.
Oncotarget28700www.oncotarget.com
30. Slaby O, Sobkova K, Svoboda M, Garajova I, Fabian P, 
Hrstka R, Nenutil R, Sachlova M, Kocakova I, Michalek 
J, Smerdova T, Knoflickova D, Vyzula R. Significant 
overexpression of Hsp110 gene during colorectal cancer 
progression. Oncol Rep. 2009; 21:1235–41.
31. Jass JR. Classification of colorectal cancer based 
on correlation of clinical, morphological and 
molecular features. Histopathology. 2007; 50:113–30. 
https://doi.org/10.1111/j.1365-2559.2006.02549.x.
32. Buhard O, Lagrange A, Guilloux A, Colas C, Chouchene 
M, Wanherdrick K, Coulet F, Guillerm E, Dorard C, Marisa 
L, Bokhari A, Greene M, El-Murr N, et al. HSP110 T17 
simplifies and improves the microsatellite instability testing 
in patients with colorectal cancer. J Med Genet. 2016; 
53:377–84. https://doi.org/10.1136/jmedgenet-2015-103518.
33. Goel A, Nagasaka T, Hamelin R, Boland CR. An optimized 
pentaplex PCR for detecting DNA mismatch repair-
deficient colorectal cancers. PLoS One. 2010; 5:e9393. 
https://doi.org/10.1371/journal.pone.0009393.
34. Vilar E, Tabernero J. Molecular dissection of microsatellite 
instable colorectal cancer. Cancer Discov. 2013; 3:502–11. 
https://doi.org/10.1158/2159-8290.CD-12-0471.
35. Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, 
Kalady MF, Lau MW, Lu KH, Roach N, Limburg PJ, and 
American Society of Clinical Oncology, and European 
Society of Clinical Oncology. Hereditary colorectal 
cancer syndromes: american society of clinical oncology 
clinical practice guideline endorsement of the familial risk-
colorectal cancer: european society for medical oncology 
clinical practice guidelines. J Clin Oncol. 2015; 33:209–17. 
https://doi.org/10.1200/JCO.2014.58.1322.
36. Gupta S, Provenzale D, Regenbogen SE, Hampel H, Slavin 
TP Jr, Hall MJ, Llor X, Chung DC, Ahnen DJ, Bray T, 
Cooper G, Early DS, Ford JM, et al. NCCN Guidelines 
Insights: genetic/familial high-risk assessment: colorectal, 
version 3.2017. J Natl Compr Canc Netw. 2017; 15:1465–
75. https://doi.org/10.6004/jnccn.2017.0176.
37. Patil DT, Bronner MP, Portier BP, Fraser CR, Plesec TP, 
Liu X. A five-marker panel in a multiplex PCR accurately 
detects microsatellite instability-high colorectal tumors 
without control DNA. Diagn Mol Pathol. 2012; 21:127–33. 
https://doi.org/10.1097/PDM.0b013e3182461cc3.
38. Cicek MS, Lindor NM, Gallinger S, Bapat B, Hopper 
JL, Jenkins MA, Young J, Buchanan D, Walsh MD, Le 
Marchand L, Burnett T, Newcomb PA, Grady WM, et 
al. Quality assessment and correlation of microsatellite 
instability and immunohistochemical markers among 
population- and clinic-based colorectal tumors results from 
the Colon Cancer Family Registry. J Mol Diagn. 2011; 
13:271–81. https://doi.org/10.1016/j.jmoldx.2010.12.004.
39. Zhang L. Immunohistochemistry versus microsatellite 
instability testing for screening colorectal cancer patients at risk 
for hereditary nonpolyposis colorectal cancer syndrome. Part 
II. The utility of microsatellite instability testing. J Mol Diagn. 
2008; 10:301–7. https://doi.org/10.2353/jmoldx.2008.080062.
40. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, 
Cunningham JM, Sargent DJ, Walsh-Vockley C, Petersen 
GM, Walsh MD, Leggett BA, Young JP, Barker MA, Jass JR, 
et al. Immunohistochemistry versus microsatellite instability 
testing in phenotyping colorectal tumors. J Clin Oncol. 2002; 
20:1043–8. https://doi.org/10.1200/JCO.2002.20.4.1043.
41. Lin CH, Lin JK, Chang SC, Chang YH, Chang 
HM, Liu JH, Li LH, Chen YT, Tsai SF, Chen WS. 
Molecular profile and copy number analysis of sporadic 
colorectal cancer in Taiwan. J Biomed Sci. 2011; 18:36. 
https://doi.org/10.1186/1423-0127-18-36.
42. Xicola RM, Llor X, Pons E, Castells A, Alenda C, Piñol V, 
Andreu M, Castellví-Bel S, Payá A, Jover R, Bessa X, Girós 
A, Duque JM, et al, and Gastrointestinal Oncology Group 
of the Spanish Gastroenterological Association. Performance 
of different microsatellite marker panels for detection of 
mismatch repair-deficient colorectal tumors. J Natl Cancer 
Inst. 2007; 99:244–52. https://doi.org/10.1093/jnci/djk033.
43. Goldstein JB, Wu W, Borras E, Masand G, Cuddy A, Mork 
ME, Bannon SA, Lynch PM, Rodriguez-Bigas M, Taggart 
MW, Wu J, Scheet P, Kopetz S, et al. Can microsatellite 
status of colorectal cancer be reliably assessed after 
neoadjuvant therapy? Clin Cancer Res. 2017; 23:5246–54. 
https://doi.org/10.1158/1078-0432.CCR-16-2994.
44. Markovic S, Antic J, Dimitrijevic I, Zogovic B, Bojic 
D, Svorcan P, Markovic V, Krivokapic Z. Microsatellite 
instability affecting the T17 repeats in intron 8 of HSP110, 
as well as five mononucleotide repeats in patients with 
colorectal carcinoma. Biomark Med. 2013; 7:613–21. 
https://doi.org/10.2217/bmm.13.46.
45. Wang XY, Chen X, Manjili MH, Repasky E, Henderson R, 
Subjeck JR. Targeted immunotherapy using reconstituted 
chaperone complexes of heat shock protein 110 and 
melanoma-associated antigen gp100. Cancer Res. 2003; 
63:2553–60.
46. Andreasson C, Fiaux J, Rampelt H, Druffel-Augustin S, 
Bukau B. Insights into the structural dynamics of the Hsp110-
Hsp70 interaction reveal the mechanism for nucleotide 
exchange activity. Proc Natl Acad Sci U S A. 2008; 
105:16519–24. https://doi.org/10.1073/pnas.0804187105.
47. Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, 
Henderson R, Subjeck JR. HSP110-HER2/neu chaperone 
complex vaccine induces protective immunity against 
spontaneous mammary tumors in HER-2/neu transgenic 
mice. J Immunol. 2003; 171:4054–61.
48. Ceballos E, Munoz-Alonso MJ, Berwanger B, Acosta 
JC, Hernandez R, Krause M, Hartmann O, Eilers M, 
Leon J. Inhibitory effect of c-Myc on p53-induced 
apoptosis in leukemia cells. Microarray analysis reveals 
defective induction of p53 target genes and upregulation 
of chaperone genes. Oncogene. 2005; 24:4559–71. 
https://doi.org/10.1038/sj.onc.1208652.
49. Shia J. Immunohistochemistry versus microsatellite instability 
testing for screening colorectal cancer patients at risk for 
hereditary nonpolyposis colorectal cancer syndrome. Part 
Oncotarget28701www.oncotarget.com
I. The utility of immunohistochemistry. J Mol Diagn. 2008; 
10:293–300. https://doi.org/10.2353/jmoldx.2008.080031.
50. Murphy KM, Zhang S, Geiger T, Hafez MJ, Bacher J, 
Berg KD, Eshleman JR. Comparison of the microsatellite 
instability analysis system and the Bethesda panel 
for the determination of microsatellite instability in 
colorectal cancers. J Mol Diagn. 2006; 8:305–11. 
https://doi.org/10.2353/jmoldx.2006.050092.
51. Kawakami H, Zaanan A, Sinicrope FA. Microsatellite 
instability testing and its role in the management of 
colorectal cancer. Curr Treat Options Oncol. 2015; 16:348. 
https://doi.org/10.1007/s11864-015-0348-2.
52. Cancer Genome Atlas Network. Comprehensive molecular 
characterization of human colon and rectal cancer. Nature. 
2012; 487:330–7. https://doi.org/10.1038/nature11252.
